KOSDAQBiotech & Pharma086820

Bio Solution

₩4,505▼ 0.44%2026-11-18 close
Market Cap
₩116.8B
Turnover
₩48,254,095
Volume
10K
Shares out.
25.9M
PER
60.3×
PBR
3.0×
EPS
₩78
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowing, 2025 profit turn, clinical expansion

Bio Solution turned its 2025 net profit attributable to controlling shareholders positive, yet operating losses have run for five consecutive quarters through the third quarter of 2026, so the durability of its earnings is the next question to watch.

  1. 1

    Revenue rose from KRW 10.1 billion in 2022 to KRW 15.2 billion in 2025, with three straight years of growth from 2023.

  2. 2

    Operating margin narrowed from -52.4% in 2022 to -28.6% in 2025, but the operating loss in 2025 was still KRW 4.34 billion.

  3. 3

    Net profit attributable to controlling shareholders turned positive in 2025 at KRW 273 million, and the company cited profit and loss related to associate investments as a main factor.

  4. 4

    The third-quarter 2026 operating loss narrowed to KRW 35.75 million, the smallest of the five quarters from the third quarter of 2025 through the third quarter of 2026.

  5. 5

    Overseas and pipeline milestones clustered in 2026, including CartiLife's sales approval in Hainan, China, the domestic IND approval for speroQure, and selection for a global regulatory support program.

02

Business structure

Bio Solution is a specialty advanced biopharmaceutical company that develops and sells cell therapy products and human tissue models.

Its flagship autologous cartilage cell therapy, CartiLife, received a formal product approval change from the Ministry of Food and Drug Safety in April 2025 and is on the market in Korea.

The pipeline includes CartiLoiD, an allogeneic cartilage cell therapy, and speroQure, an injectable disease-modifying osteoarthritis candidate. CartiLoiD is in a Phase 1/2 trial in Australia, and speroQure received domestic Phase 1/2a IND approval in July 2026.

According to FnGuide's breakdown for 2024, revenue comprised cell therapy 73.55%, cosmetic materials 11.96%, human tissue models 10.02%, services 2.27% and merchandise 2.19%.

The company's skin and cornea tissue models carry OECD test guideline listings, and its skin model holds ISO certification, supporting model sales and alternative-testing services. Its burn treatment product Kerahill-Allo is covered by national health insurance and industrial accident insurance.

In China, CartiLife received sales approval in Hainan's Boao Lecheng medical zone in April 2026 and began its first patient treatment in August 2026. In the United States, CartiLife completed a Phase 2 trial, received RMAT designation from the FDA in 2023, and discussed its Phase 3 strategy with the agency.

Osteoarthritis care is dominated by symptom-relief therapy, leaving substantial unmet demand for drugs that slow disease progression. The company is pursuing a two-track approach, using autologous products to build the domestic base and allogeneic products to widen indications and ease treatment.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.5B-₩1.1B−24.4%
2025Q4₩4.4B-₩500M−11.0%
2026Q1₩3.8B-₩1.3B−34.5%
2026Q2₩4.7B-₩500M−10.3%
2026Q3₩5.1B-₩35,745,706−0.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩10.1B-₩5.3B-₩8.1B−52.4%−18.5%109.5%
2023₩12.5B-₩5B-₩1.2B−40.4%−3.0%119.0%
2024₩12.9B-₩5.1B-₩11.9B−39.3%−38.2%115.8%
2025₩15.2B-₩4.3B₩300M−28.6%0.9%114.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual revenue rose from KRW 10.1 billion in 2022 to KRW 12.5 billion in 2023, KRW 12.9 billion in 2024 and KRW 15.2 billion in 2025, with 2025 up 17.9% year on year and three straight years of growth from 2023.

The operating loss was KRW 5.29 billion in 2022, KRW 5.03 billion in 2023, KRW 5.07 billion in 2024 and KRW 4.34 billion in 2025, widening in 2024 before narrowing in 2025, and the company has recorded an operating loss for four consecutive years.

Operating margin improved from -52.4% in 2022 to -40.4%, -39.3% and -28.6% in 2025, suggesting that revenue growth has been narrowing the loss.

Net loss attributable to controlling shareholders was KRW 8.09 billion in 2022, KRW 1.25 billion in 2023 and KRW 11.9 billion in 2024, before turning to a net profit of KRW 273 million in 2025, and net profit including non-controlling interests was also KRW 273 million that year.

The company attributed the main drivers of the 2025 result to stronger sales of domestically marketed products and to profit and loss related to associate investments.

Because the profit arrived while the operating loss remained, the contribution of non-operating items should be separated from any recovery in core operations.

Quarterly revenue went from KRW 4.51 billion in the third quarter of 2025 to KRW 4.42 billion in the fourth quarter (down 2.1% quarter on quarter), then hit a low of KRW 3.76 billion in the first quarter of 2026 (down 14.8%), before rising to KRW 4.7 billion in the second quarter (up 25.0%) and KRW 5.12 billion in the third quarter (up 8.8%, or 13.4% year on year).

Quarterly operating losses were KRW 1.1 billion in the third quarter of 2025, KRW 485 million in the fourth quarter, KRW 1.3 billion in the first quarter of 2026, KRW 482 million in the second quarter and KRW 35.75 million in the third quarter, the smallest of the five quarters on the filed record.

Net profit attributable to controlling shareholders turned positive at KRW 5.5 billion in the fourth quarter of 2025, then recorded losses of KRW 2.04 billion, KRW 736 million and KRW 1.02 billion in the first three quarters of 2026, making three straight loss quarters.

The combined total for the last four quarters, KRW 1.7 billion, depends on the fourth-quarter 2025 profit, and without that quarter the total would be a loss.

At year-end 2025, total equity stood at KRW 32 billion, total liabilities at KRW 36.5 billion, and the debt-to-equity ratio at 114.0%, after 109.5% in 2022, 119.0% in 2023 and 115.8% in 2024.

Operating cash flow was -KRW 3.81 billion in 2022, KRW 2.16 billion in 2023, -KRW 2.29 billion in 2024 and -KRW 1.31 billion in 2025, so cash generation from core operations has not yet been stable.

05

Industry analysis

The osteoarthritis treatment market is centered on symptom-relief therapy, which leaves substantial unmet demand for drugs that slow disease progression itself.

Autologous cell therapies require harvesting a patient's own cells, expanding them and reimplanting them, so surgical tissue collection and production time weigh on the model.

An independent research note argued that CartiLoiD, an allogeneic product, can be produced in bulk in off-the-shelf form, supporting cost competitiveness and scalability.

The same note described a two-track structure in which CartiLife covers the premium customized segment and CartiLoiD targets a broader general patient population. On regulation, the FDA granted CartiLife RMAT designation in 2023, and CartiLoiD and speroQure are preparing U.S. IND submissions.

In China, the approval pathway in Hainan's Boao Lecheng medical zone became the first commercial stage, and mainland expansion is at the stage of reviewing regulatory and clinical routes with local partners.

Kerahill-Allo, a burn treatment, is covered by national health insurance and industrial accident insurance, so reimbursement status affects domestic prescribing and the pace of sales.

On alternative testing, the company showcased an animal-free testing solution with Merck Life Sciences in August 2026, widening its collaboration in tissue models.

In competitive terms, the company has secured the domestic market with autologous products and is now extending through allogeneic products and overseas trials, so commercialization speed and pipeline progress will be compared together.

06

Outlook

The forward schedule the company has disclosed centers on clinical and regulatory milestones.

On September 22, 2026, the company said it had been selected for the regulatory response cost support category of the Korea Health Industry Development Institute's second 2026 pharmaceutical and bio global expansion support program.

Under this project, the company is starting regulatory strategy and documentation work for U.S. IND submissions for CartiLoiD and speroQure, with product-by-product gap analysis and CTD/eCTD document preparation scheduled in sequence. CartiLife discussed its U.S.

Phase 3 development strategy with the FDA in a Type C meeting, and the company plans to firm up Phase 3 preparations, including the trial protocol and statistical analysis plan, based on that outcome.

In China, CartiLife began its first treatment at a Boao International Hospital in Hainan in August 2026, and the company says it will accumulate real-world usage data to explore expansion in the Chinese market. speroQure received domestic Phase 1/2a IND approval for knee osteoarthritis in July 2026 and plans to enroll up to 18 patients in Phase 1 and 41 to 68 in Phase 2a.

CartiLoiD is in a Phase 1/2 trial in Australia. An independent research note reported on October 22, 2026 described 2026 as the year core pipeline programs enter active clinical stages, and it did not state an investment rating or target price.

The next periodic report is the 2026 annual report, which will settle the annual operating loss and the durability of fourth-quarter profit. Whether the U.S. clinical entry and the mainland China partnership translate into actual revenue will determine the business structure from 2027 onward.

07

Valuation

PER
60.3×
PBR
3.0×
ROE
5.1%
EPS
₩78
BPS
₩1,590
Dividend per share
₩0

The current multiples reflect a very small earnings base over the last four quarters, so earnings multiples alone do not explain the share price level.

The combined net profit attributable to controlling shareholders for the last four quarters is KRW 1.7 billion, and excluding the KRW 5.5 billion profit in the fourth quarter of 2025 would turn that total into a loss. The denominator of any earnings multiple therefore depends heavily on a single quarter's profit.

The 2025 full-year net profit attributable to controlling shareholders was KRW 273 million, a shift from loss to profit, but the earnings base remains small.

The price-to-book level sits in a range with a large premium over net asset value of KRW 32 billion, and how quickly accumulated earnings build equity will determine whether that gap narrows. The company does not pay a dividend, so comparisons based on dividend yield do not apply.

Pipeline value is only partly reflected in current earnings, so how the market values each clinical stage will change how multiples are read. The amended convertible bond issuance decision filed on August 6, 2026 means possible changes in the share count also enter the interpretation of multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Sustained revenue growth

Revenue grew for three straight years from 2023 and rose 17.9% in 2025. It increased in the second and third quarters of 2026, and third-quarter revenue was up 13.4% year on year. Improving profitability alongside the larger revenue base is the core of this trend.

Narrowing losses and a profit turn

The operating margin narrowed from -52.4% in 2022 to -28.6% in 2025, and net profit attributable to controlling shareholders turned positive at KRW 273 million in 2025. The third-quarter 2026 operating loss of KRW 35.75 million was the smallest of the five filed quarters. The company cited stronger sales of its domestically marketed products as a factor behind the 2025 result.

Overseas trials and commercialization progress

CartiLife received sales approval in Hainan, China in April 2026 and began its first treatment in August.

In the United States it completed a Phase 2 trial, received RMAT designation in 2023 and discussed the Phase 3 strategy with the FDA. speroQure received domestic Phase 1/2a IND approval in July 2026 and was selected for a regulatory cost support program in September.

09

Bear factors

Persistent operating losses

The operating loss has persisted for four consecutive years through 2025, and the company has posted losses in five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. The first-quarter 2026 operating loss widened to KRW 1.3 billion from the prior quarter. Unlike the profit turn at the controlling-shareholder level, the operating business still runs at a loss.

Balance sheet and cash flow pressure

Total liabilities at the end of 2025 were KRW 36.5 billion, with a debt-to-equity ratio of 114.0%. Operating cash flow was negative for two years in a row, at -KRW 2.29 billion in 2024 and -KRW 1.31 billion in 2025.

The company said the 2025 profit reflected associate-investment profit and loss, which should be distinguished from any improvement in core cash generation.

Clinical timing and funding uncertainty

The U.S. Phase 3 trial and the FDA IND submissions for CartiLoiD and speroQure are at the preparation stage, and specific timing has not been disclosed. Mainland China entry is under discussion with local partners, so the timing of revenue is open.

A convertible bond issuance decision amended in August 2026 means funding and share dilution also need to be weighed.

10

Risk factors

Clinical and regulatory

Entry into the U.S. Phase 3 trial for CartiLife and the FDA IND reviews for CartiLoiD and speroQure are variables the company cannot fully control. Results that fall short or review delays could weigh on the valuation of the whole pipeline.

Revenue remains concentrated in Korea and parts of China, so growth may stay limited until overseas approval scope widens.

Funding and dilution

An amended convertible bond issuance decision was filed on August 6, 2026. Conversion would increase the number of shares and affect per-share metrics. Given that operating cash flow was -KRW 1.31 billion in 2025, further external funding remains a possibility.

Overseas commercialization

Treatments in Hainan began with the first patient in August 2026, and mainland entry is still under partner talks and a review of regulatory and clinical routes. Until overseas sales appear in filings, their contribution to consolidated results is hard to gauge.

Without wider treatment volumes and new sales regions, overseas business may struggle to become the main driver of earnings improvement.

11

What to watch next

  1. End of March 2027 (annual report filing deadline)

    The 2026 annual report will confirm full-year revenue, operating loss and fourth-quarter net profit attributable to controlling shareholders. How the five quarters of operating losses through the third quarter of 2026 settle on an annual basis is the point to check.

  2. Mid-May 2027 (first-quarter 2027 quarterly report deadline)

    Whether first-quarter 2027 revenue holds near the KRW 5.12 billion level of the third quarter of 2026, and whether Hainan treatment revenue appears, will show whether growth is continuing.

  3. After November 2026 (timing not disclosed)

    Whether and when CartiLoiD and speroQure are submitted for U.S. FDA IND review. Submission would be the first formal step toward U.S. clinical entry and a milestone for regulatory progress.

  4. After November 2026 (timing not disclosed)

    Whether a local partnership is signed for CartiLife's mainland China entry. Expansion beyond Hainan will be the test of whether overseas revenue can scale.

  5. Conversion request timing (after November 2026)

    Conversion requests under the convertible bonds amended on August 6, 2026, and the resulting change in share count. Once the dilution scale is set, per-share metrics can be interpreted more precisely.

12

Overall view

Bio Solution's revenue rose to KRW 15.2 billion in 2025 from KRW 10.1 billion in 2022, and net profit attributable to controlling shareholders turned positive in 2025.

However, the operating loss was KRW 4.34 billion in 2025, and operating losses have run for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, so break-even in core operations has not yet been reached.

The company explained the 2025 profit as reflecting profit and loss related to associate investments, and net losses followed in the first three quarters of 2026 after the fourth-quarter 2025 profit.

The balance sheet carries a debt-to-equity ratio of 114.0% alongside negative operating cash flow, so funding capacity and the cost of pipeline investment are the key issues.

Bullish factors are continued revenue growth, a narrowing operating loss and progress in CartiLife's overseas commercialization, while bearish factors are persistent operating losses, financial burden, and uncertainty over clinical timing and overseas revenue realization.

On valuation, the small earnings base over the last four quarters pushes multiples high, and pipeline value is only partly reflected in current earnings. The next checkpoints are the 2026 annual report due by the end of March 2027 and the first-quarter 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. thevc.kr
  3. comp.wisereport.co.kr
  4. asp01.fnguide.com
  5. thinkpool.com
  6. ssl.pstatic.net
  7. comp.fnguide.com
  8. m.news.nate.com
  9. markets.hankyung.com
  10. mt.co.kr
  11. supple.kr
  12. biosolutions.irpage.co.kr
  13. thebionews.net
  14. supple.kr
  15. mt.co.kr
  16. newspim.com
  17. eduinfom.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis